Evidence map›Paper›PMID 40693273›Full record

ArticleFrontiers in pharmacology2025

Exploration of the potential neurotransmitter or neuromodulator-like properties of harmine: evidence from synthesis to synaptic modulation.

Zhejun Xie, Ning Cao, Manlin Li, Hanxue Wang, Huida Guan, Xuemei Cheng, Changhong Wang

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhejun Xie *The MOE Key Laboratory for Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Ning Cao *The MOE Key Laboratory for Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Manlin LiThe MOE Key Laboratory for Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Hanxue WangShanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Huida GuanThe MOE Key Laboratory for Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xuemei ChengThe MOE Key Laboratory for Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Changhong WangThe MOE Key Laboratory for Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The discovery of new neurotransmitters is crucial for the in-depth understanding of neural signal transmission, neurological disorders, and relevant treatment strategies. Emerging evidence has indicated that harmine is an important endogenous compound, and its level is closely related to different physiological and disease states. Inspired by this, we propose a hypothesis that harmine may be a potential neurotransmitter or neuromodulator and display neurotransmitter or neuromodulator-like properties. This study aims to explore the potential properties of harmine as a neurotransmitter or neuromodulator according to the essential criteria for neurotransmitters and neuromodulators. Methods: Candidate proteins for the biosynthesis of harmine were searched by local BLAST. The target protein was then recombinantly expressed, purified, and functionally validated. Subsequently, the release, metabolism, and uptake pathways of harmine were investigated using rat brain synaptosomes and primary neural cells through mass spectrometry analysis. A human proteome microarray was employed to screen for harmine-binding receptors, followed by experimental validation. Results: Adipocyte plasma membrane-associated protein isoform X1 (APMAP-X1) could effectively catalyze the Pictet-Spengler reaction in mammals to generate tetrahydroharmine, which was subsequently oxidized by myeloperoxidase (MPO) to produce harmine. Moreover, harmine could be metabolized, taken up, and released within the synaptic cleft, fulfilling the conditions for clearance and release within the synaptic cleft. Harmine also regulated the expression of neurotransmitter transporters, implying its potential neuromodulatory properties. G protein-coupled receptor 85 (GPR85) and chloride intracellular channel 2 (CLIC2) were receptors targeted by harmine in the central nervous system. Functional verification results confirmed that harmine exerted an inhibitory effect on the GPR85 and could induce cellular depolarization. Conclusion: Current findings provide preliminary evidence that harmine may exhibit neurotransmitter-like properties in certain respects and support its role as an endogenous neuromodulator. However, direct evidence supporting harmine as a neurotransmitter remains limited. Further studies are needed to clarify the precise mechanisms of harmine in neurotransmission. Our study provides a new perspective for researchers on exploring novel endogenous molecules and their significance in neurophysiology.

Indexed as

adipocyte plasma membrane-associated proteincentral nervous systemharmineneuromodulatorneurotransmitterreceptor interaction

Identifiers

PMID40693273
PMCPMC12277293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.